Pfizer Equity Securities Without Readily Determinable Fair Value - Cumulative Impairment Loss decreased by 4.9% to $444.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 11.0%, from $400.00M to $444.00M.
equity_securities_no_fv_impairment_cumulative| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $93.00M | $95.00M | $110.00M | $108.00M | $148.00M | $171.00M | $170.00M | $188.00M | $293.00M | $306.00M | $323.00M | $400.00M | $435.00M | $467.00M | $444.00M |
| QoQ Change | — | +2.2% | +15.8% | -1.8% | +37.0% | +15.5% | -0.6% | +10.6% | +55.9% | +4.4% | +5.6% | +23.8% | +8.8% | +7.4% | -4.9% |
| YoY Change | — | — | — | +16.1% | +55.8% | +55.5% | +57.4% | +27.0% | +71.3% | +80.0% | +71.8% | +36.5% | +42.2% | +44.6% | +11.0% |